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Abstract
Colon carcinogenesis consists of a multistep process during which a series of genetic and epigenetic adaptations occur that
lead to malignant transformation. Here, we have studied the role of A20 (also known as TNFAIP3), a ubiquitin-editing
enzyme that restricts NFkB and cell death signaling, in intestinal homeostasis and tumorigenesis. We have found that A20
expression is consistently reduced in human colonic adenomas than in normal colonic tissues. To further investigate A20’s
potential roles in regulating colon carcinogenesis, we have generated mice lacking A20 specifically in intestinal epithelial
cells and interbred these with mice harboring a mutation in the adenomatous polyposis coli gene (APCmin). While A20FL/FL
villin-Cre mice exhibit uninflamed intestines without polyps, A20FL/FL villin-Cre APCmin/+ mice contain far greater numbers
and larger colonic polyps than control APCmin mice. We find that A20 binds to the b-catenin destruction complex and
restricts canonical wnt signaling by supporting ubiquitination and degradation of b-catenin in intestinal epithelial cells.
Moreover, acute deletion of A20 from intestinal epithelial cells in vivo leads to enhanced expression of the b-catenin
dependent genes cyclinD1 and c-myc, known promoters of colon cancer. Taken together, these findings demonstrate new
roles for A20 in restricting b-catenin signaling and preventing colon tumorigenesis.
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Introduction
Colon cancer is the second leading cause of cancer deaths in the
USA; hence, understanding its pathogenesis remains a critical
goal. Both germ line and somatic mutations in a number of genes
have been described to contribute to colon cancer. These
mutations contribute to colon carcinogenesis by perturbing cell
cycling, cell survival, DNA repair and other critical cellular
homeostasis functions [1]. For example, mutations in the
adenomatous polyposis coli (APC) gene lead to stabilization of
the b-catenin protein, increased transcription of wnt stimulated
genes, and perturbed intestinal epithelial cell proliferation and
differentiation [2,3]. In addition, epigenetic factors such as chronic
intestinal inflammation increase the risk of malignant transforma-
tion [4–6]. The link between chronic inflammation and cancer
may involve NFkB dependent signals, as continuous activation of
the NFkB pathway causes spontaneous intestinal tumors in mice,
and intestinal epithelial cell (IEC) specific ablation of IKKb,
protects mice from inflammation associated colon tumors [7,8].
A20 is a potent anti-inflammatory enzyme, as global loss of A20
leads to multi-organ inflammation and perinatal lethality [9]. A20
performs its anti-inflammatory functions by restricting ubiquitin
dependent NFkB and cell death signals [9–13]. A20 is a
biochemically intriguing protein that exhibits de-ubiquitinating,
E3 ligase and ubiquitin binding activities. A20 binds to ubiquitin
chains and ubiquitinated signaling complexes and regulates the
quantity and type of polyubiquitin chains in these complexes.
These chains in turn regulate the activity and stability of signaling
proteins such as RIP1, RIP2 and TRAF6[14–16]. A20’s anti-
inflammatory functions are important for human disease, as
genome wide association studies (GWAS) have linked polymor-
phisms of the A20/TNFAIP3 gene to multiple inflammatory and
autoimmune diseases including inflammatory bowel disease[17–
22]. At least some of these polymorphisms cause reduced
expression or function of A20 [23,24].
While A20’s ability to inhibit NFkB signaling suggests that it
may prevent inflammation association malignancies, A20’s capac-
ity to inhibit cell death suggests that it might also promote
tumorigenesis by protecting cancer cells from apoptosis. The
discovery that bi-allelic somatic mutations of the A20 gene occur
in up to 30% of Hodgkin’s lymphoma, MALT, marginal zone,
and diffuse large B-cell lymphomas indicated that A20 functions as
a tumor suppressor in B cells [25]. However, A20’s NFkB
inhibitory functions and cell death inhibitory functions may be
integrated differently in distinct cell-types. We have thus investi-
gated A20’s functions in intestinal epithelial cell (IEC) homeostasis
and tumorigenesis.
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Materials and Methods
Antibodies and Reagents
Antibodies directed against A20 (Cell Signaling, 5630; Santa
Cruz, sc-376564; Santa Cruz, sc-69980), Active b-catenin
(Mllipore, 05–665), Axin (Cell Signaling, 2087), Total b-catenin
(Santa Cruz, sc-1496), FLAG (Sigma, F3165), GAPDH (Millipore,
MAB374), HA (Santa Cruz, sc-805), MYC (Santa Cruz, sc-789),
and pan-ubiquitin (SC-8017) were used for immunoprecipitation
and western blot as described below. RKO cells were obtained
from the ATCC and maintained in DMEM (Cellgro) supple-
mented with 10% FCS (Atlanta Biologicals), 1% penicillin-
streptomycin-glutamine (Cellgro), and 25 mM HEPES (Cellgro).
Recombinant human wnt3a was purchased from R&D systems
(5036-WN-010).
Mice
A20FL mice were generated in our laboratory and described
previously [26]. APCmin and villin-Cre mice were purchased from
JAX. Transgenic mice harboring a tamoxifen-inducible Cre
recombinase under the control of the villin-promoter (villin-ER/
Cre) were a kind gift from S. Robine (Institut Curie-CNRS, Paris,
France). Acute deletion of A20 was performed as previously
described [27]. Briefly 1 mg tamoxifen (Sigma, T5648) was
dissolved in sterile corn oil and injected intraperitoneally daily
for five consecutive days. Tumor number and burden was
determined at four months of age with the aid of a stereomicro-
scope equipped with a sizing reticle (Klarman Rulings, Litchfield
NH). All animal studies were conducted in accordance with the
University of California, San Francisco Institutional Animal Care
and Use Committee.
Immunoprecipitation and Immunoblotting
Freshly isolated intestinal epithelial cells or RKO cells were
lysed in ice-cold 0.5% Triton X-100 (Sigma, BP151) containing
50 mM Tris HCl pH 7.4, 150 mM NaCl, and 10% glycerol and a
protease inhibitor cocktail (Roche Complete EDTA-free). For
studies concerning ubiquitin modifications, the lysis buffer was also
supplemented with 10 mM orthophenanthroline (Sigma, P9375),
10 mM iodoacetamide (Sigma, I6125), and the proteasome
inhibitor, MG132 (Enzo, BML-PI102) at a final concentration of
10 uM. The insoluble fraction was removed by centrifugation at
14,000 rpm for 25 minutes in a tabletop centrifuge. Protein
concentrations were determined by BCA Assay (Thermo Scien-
tific). For immunoprecipitation, equal amounts of protein were
incubated overnight with 3 ug of antibody. Lysates were then
immunoprecipitated using protein G Dynabeads (Invitrogen)
according to the manufacturers instructions. Samples were
resolved on NuPage precast 4–12% Bis-Tris gels (Invitrogen)
and transferred to PVDF for western blot analysis.
Transfection and Luciferase Assays
siRNA to human A20 (59 GAA GCU CAG AAU CAG AGA
UUU 39) or a control scrambled siRNA (59 AAC GUA CGC
GGA AUA CUU CGA 39) was purchased from Dharmacon. The
MegaTOPFlash luciferase reporter was a kind gift from Dr. Roel
Nusse (Stanford University, CA). The pRL-Renilla vector and
dual luciferase reporter assay system were obtained from Promega.
RKO cells were seeded in 24-well tissue culture plates (Costar) in
antibiotic-free media. Twenty-four hours prior to stimulation with
recombinant human wnt3a, siRNA (30 pmoles), MegaTOPFlash
(500 ng), and Renilla (0.1 ng) was transiently transfected using
Lipofectamine (Invitrogen) according to the manufacturers
instructions. Twelve hours prior to stimulation with recombinant
human wnt3a, cells were cultured in media containing 2% fetal
calf serum. Fresh media containing 2% FCS and 150 ng/mL
wnt3a was added to the cells for eight hours prior to harvest and
determination of luciferase activity. Firefly luciferase activity was
normalized to Renilla luciferase activity.
Figure 1. Human colonic adenomas express less A20 than
normal colonic mucosa. Expression of A20 (top panel), cyclin D1
(middle panel) and c-myc (bottom panel) mRNAs in normal colonic
mucosa and colonic adenomas, as quantitated by the Genome
Expression Omnibus (GDS2947). Relative expression levels are shown.
**indicates p,0.01.
doi:10.1371/journal.pone.0062223.g001
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Plasmids and Cloning
Full-length human A20 and Axin cDNA were obtained from
OpenBiosystems. Murine full length A20 was cloned from
mouse embryonic fibroblasts. N- and C-terminal truncation
mutants were generated by FspI (NEB) digestion. The N-
terminal fragment consists of amino acids 1–384 and terminates
just prior to zinc finger 1. The C-terminal mutant consists of
amino acids 369–775 and begins just prior to zinc finger 1.
Full-length human and mouse, truncated murine A20 constructs
and Axin were cloned into pCMV-3Tag (Agilent) vectors
containing a N-terminal 3FLAG or 3MYC epitope tag
respectively. A20 deficient RKO cells were generated by
TALEN technology [28]. TALEN targeting sequences are
available upon request.
Primary Intestinal Epithelial Cell Isolation and
Quantitative PCR
Murine intestinal epithelial cells were isolated using the protocol
of G.S. Evans with some modifications [29]. Briefly, intestines
were excised and placed in ice-cold HBSS (Cellgro) containing 2%
glucose (Sigma). Intestines were flushed with HBSS containing
1 mM DTT to remove fecal contents and then opened along their
antimesenteric side. Intestinal segments were cut into 2–3 mm
sections and then washed five times in ice-cold HBSS with 2%
glucose. After washing, intestinal sections were incubated with
Ca2+ and Mg2+ free PBS containing 10 mM EDTA for 30 minutes
at room temperature with gentle agitation. After incubation,
samples were agitated briefly to release epithelial cells. The
supernatant, containing enriched epithelial cells, was collected and
washed in ice-cold HBSS with 2% glucose.
Total RNA was isolated by Trizol (Invitrogen) according to the
manufacturers instructions. One microgram of total RNA was
used for reverse transcription using the Quantitech Reverse
Transcription kit (Qiagen). Quantitative PCR was performed
using the following Taqman primers (Applied Biosystems,
Carlsbad CA): TNFAIP3 (Mm00437122_m1), Cyclin D1
(Mm00432359_m1), MYC (Mm00487803_m1), HPRT1
(Mm00446968_m1). Quantitative PCR was performed using the
Gene Expression Master Mix (Applied Biosystems, 4369016) on
an ABI 7300 using the following protocol: 50u 2 min, 95u 10 min,
95u 15 sec, 60u 1 min for 40 cycles. Ct values were normalized to
HPRT1 values.
Immunohistochemistry
Resected intestinal tissue was fixed in 10% neutral-buffered
formalin (Sigma) overnight. Tissue specimens were then
embedded in paraffin and stained according to standard
protocols.
Figure 2. A20 expression in IECs restricts colon tumorigenesis. (A) immunoblot analysis of isolated IECs indicating efficient deletion of A20
from the small bowel (SB) and colon (C) of villin-Cre A20FL/FL APCmin/+ mice (fl/fl) compared to control villin-Cre A20+/+ APCmin/+ mice (+/+) mice.
GAPDH is shown as a loading control. (B) Tumor number (left panel) and aggregate tumor size (right panel) in colons of A20 (fl/fl) and wild-type (+/+)
mice harboring APCmin mutation. (C) Tumor numbers in small intestines of A20 (fl/fl) and wild-type (+/+) mice harboring APCmin mutation. (D) Colon
and small intestine lengths from (fl/fl) and wild-type (+/+) mice harboring APCmin mutation. Each point represents one mouse. Lines indicate mean
values. (f) Hematoxylin and eosin staining (upper panels) and Ki-67 and cleaved caspase-3 immunostaining (lower panels) of colonic sections from
villin-Cre A20FL/FL APCmin/+ mice (fl/fl) and control villin-Cre A20+/+ APCmin/+ mice. 40X magnification shown.
doi:10.1371/journal.pone.0062223.g002
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Statistical Analysis
Statistical analysis was performed with Graphpad Prism 4
(Graphpad Software, San Diego, CA). Comparisons between two
groups were performed by two-tailed unpaired Student’s t-test.
Multigroup comparisons were performed by one-way analysis of
variance. P,0.05 was used as the threshold for statistical
significance.
Results and Discussion
We first addressed potential epigenetic changes in A20
expression in colon carcinogenesis by searching NCBI’s Genome
Expression Omnibus [30,31]. We found that A20 mRNA
expression is significantly decreased in human adenomatous
colonic polyps as compared to normal surrounding tissue (Fig. 1,
Fig. S1). These human colon tumors also express increased levels
of the cell proliferation related genes c-myc and cyclinD1 (Fig. 1,
Figure S1). Several recent reports have also suggested genetic and
epistatic changes in A20 expression in human colorectal cancer
[32,33]. To directly test A20’s potential cell-autonomous functions
in IECs, we generated mice lacking A20 specifically in these cells
by interbreeding A20FL mice with villin-Cre transgenic mice [26].
Compound A20FL/FL villin-Cre mice effectively eliminated A20
protein expression from both small intestinal and colonic epithelial
cells (Fig. 2A). Previous reports have shown that mice harboring an
intestinal epithelial cell-specific deletion of A20 were grossly
normal and did not exhibit spontaneous inflammation or tumor
development [34]. However, these mice were more susceptible to
induced models of colitis. Conversely, overexpression of A20 in
intestinal epithelial cells protects mice from dextran sodium sulfate
induced colitis, potentially through an enhancement of the
epithelial barrier [35,36]. To determine whether A20 expression
might predispose to colon carcinogenesis, we interbred A20FL/FL
villin-Cre mice with APCmin mice that harbor a mutation in the
APC gene [37]. Heterozygous APCmin/+ mice develop spontane-
ous intestinal tumors, while homozygous APCmin/min mice are
embryonically lethal [37,38]. Importantly, this model does not
involve gross inflammation such as that induced by repeated
dextran sulfate sodium (DSS) and the mutagen azoxymethane
(AOM). As previously reported, A20+/+ APCmin/+ mice sponta-
Figure 3. A20 supports b-catenin ubiquitination and degradation through an interaction with the destruction box. (A) Luciferase assay
showing transcriptional activity of a b-catenin dependent TCF/LEF4 reporter in RKO cells. Cells were treated with A20 specific or control siRNA and
recombinant human wnt3a (rhwnt3a) as indicated. Relative luciferase units (RLU) are shown. **indicates p,0.01. (B) Co-precipitation of A20 with
Axin. RKO cells transfected with the indicated expression plasmids were lysed, immunoprecipiated (IP) for the indicated epitope tag, and
immunoblotted (IB) for the indicated proteins. Cells were stimulated with rhwnt3a or control as indicated for four hours. Input levels of MYC, FLAG,
and GAPDH are shown as controls below. (C) Co-precipitation of partial A20 proteins with Axin. Co-transfection experiments as in (B). Input levels of
MYC, FLAG, and GAPDH shown below. (D) A20 suppresses wnt3a stimulated induction of b-catenin expression. Immunoblot analyses of active and
total b-catenin expression in RKO cells treated with A20 specific or control siRNA. A20 and GAPDH levels shown below as loading control. (E) A20
supports wnt3a stimulated b-catenin ubiquitination. RKO cells were treated with A20 specific or control siRNAs and wnt3a for the indicated times.
Lysates were immunoprecipitated for b-catenin followed by immunoblotting for ubiquitin. Input amounts of beta-catenin, A20, and GAPDH proteins
shown below as controls. All data are representative of three or more independent experiments.
doi:10.1371/journal.pone.0062223.g003
A20 Prevents Colon Cancer
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neously developed multiple small intestinal tumors but infrequent
colonic tumors (Fig. 2B, 2C). Remarkably, A20FL/FL villin-Cre
APCmin/+ mice possessed significantly increased numbers of
colonic adenomas when compared to A20+/+ villin-Cre APCmin/
+ mice (Fig. 2B). The aggregate size of colonic polyps was also
increased in these mice (Fig. 2B). The number of small bowel
polyps was not affected by A20 deficiency in small intestinal IECs
(Fig. 2C). Thus, A20 appears to regulate colonic tumorigenesis.
As A20 restricts NFkB signaling, A20 might restrict colon
tumorigenesis by preventing spontaneous intestinal inflammation
in A20FL/FL villin-Cre APCmin/+ mice. However, similar to
A20FL/FL villin-Cre and A20+/+ villin-Cre mice, no signs of
spontaneous inflammation were present in A20FL/FL villin-Cre
APCmin/+ and A20+/+ villin-Cre APCmin/+ mice, and there were
no differences in intestinal length or mouse weights (Fig. 2D, 2E).
Histologic examination of colonic neoplasms and surrounding
normal intestinal tissues did not reveal significant differences
between A20FL/FL villin-Cre APCmin/+ and A20+/+ villin-Cre
APCmin/+ mice in inflammation, apoptosis, or proliferation rates
(Fig. 2F). Thus, A20 expression in IECs does not strongly restrict
basal intestinal inflammation.
The APC gene is mutated in the majority of sporadic colorectal
adenocarcinomas [39] and in nearly all cases of familial
adenomatous polyposis [40,41]. The APC protein is part of a
multi-protein complex termed the destruction complex. This
complex, including the E3 ligase complex SCF/b-TRCP, causes
phosphorylation, ubiquitination, and degradation of b-catenin
[42]. Stimulation of cells with wnt ligands, or mutations of proteins
such as APC, interrupt this process, allowing b-catenin to migrate
to the nucleus and induce transcription of b-catenin dependent
genes [3,43]. Recently, renewed interest has arisen concerning
ubiquitination of the components of the classical wnt/b-catenin
signaling cascade as a mechanism for its regulation [44].
Given A20’s pleiotropic functions in regulating ubiquitin
dependent signals, we hypothesized that A20 might regulate wnt
signaling. To investigate this possibility, we first used an siRNA
approach to reduce A20 expression in RKO cells, a cell line with
intact wnt induced b-catenin signaling [45]. Acute knockdown of
A20 expression caused a marked increase in TCF/LEF4 luciferase
reporter activity after recombinant human wnt3a stimulation
when compared to cells transfected with control siRNA (Fig. 3A).
These results suggest that A20 directly restricts wnt induced
signaling.
To better understand how A20 restricts b-catenin signaling, we
investigated whether A20 binds to destruction complex proteins
that regulate b-catenin ubiquitination. A20 co-precipitated with
both heterologously expressed and endogenous Axin, the scaffold-
ing protein that binds many destruction complex proteins (Fig. 3B,
Figure S2). No change in this association was seen after wnt3a
stimulation, suggesting a constitutive association between these
two molecules. A20 utilizes a number of motifs to bind ubiquitin
chains, other ubiquitin binding proteins, and other ubiquitin
editing enzymes [46]. We thus tested whether A20’s N-terminal or
C-terminal domains mediate binding of A20 to Axin. Full length
A20 co-precipitated with Axin, as did (to a lesser extent) the N-
terminal OTU domain of A20 (Fig. 3C). By contrast, the C-
terminal portion of A20 containing its seven zinc fingers failed to
co-precipitate with Axin, suggesting that A20 preferentially utilizes
its N-terminal OTU domain to bind Axin (Fig. 3C). These studies
suggest that A20 interacts directly with the b-catenin destruction
complex.
As b-catenin protein levels are tightly regulated by the SCF/b-
TRCP E3 ligase complex, we tested the role of A20 in regulating
b-catenin ubiquitination and stability. Stimulation of both A20
siRNA and control siRNA knockdown RKO cells with wnt3a led
to increased levels of total b-catenin, however, A20 deficient RKO
Figure 4. Acute deletion of A20 from IECs leads to increased
levels of Cyclin D1 and MYC mRNA in vivo. Villin-ER/Cre A20FL/FL
(fl/fl) and control Villin-ER/Cre A20+/+ (+/+) were injected with 1 mg of
tamoxifen daily for 5 days. IECs were then isolated and studied for
expression of A20 (upper panel), Cyclin D1 (middle panel), and MYC
(lower panel) mRNAs by qPCR. Each point represents one mouse.
*indicates p,0.05; **indicates p,0.01.
doi:10.1371/journal.pone.0062223.g004
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cells accumulated significantly greater levels of the active
dephosphorylated form of b-catenin when compared to control
RKO cells (Fig. 3D). Notably, A20 protein levels did not increase
after wnt3a stimulation, suggesting that wnt3a does not stimulate
NFkB dependent induction of A20 expression (Fig. 3D). In
addition, increased b-catenin dependent TCF/LEF4 reporter
activity in A20 deficient RKO cells did not result from increased
b-catenin mRNA expression, suggesting that A20 regulates b-
catenin via post-transcriptional or post-translational mechanisms
(Fig. S3). Cellular b-catenin protein levels are regulated at the
post-translation level through K48-linked ubiquitination and
subsequent proteasomal degradation. To determine whether A20
regulates b-catenin ubiquitination, we stimulated RKO cells with
wnt3a ligand, immunoprecipitated b-catenin, and immunoblotted
for ubiquitin. A20 deficient cells accumulated significantly
decreased levels of ubiquitinated b-catenin than control cells,
particularly at four hours after wnt3a stimulation (Fig. 3E). These
results correspond with increased b-catenin levels in A20 deficient
cells (Fig. 3E). Taken together, these studies indicate that A20
binds to the APC destruction complex and restricts wnt3a induced
b-catenin signaling by promoting b-catenin ubiquitination and
degradation.
Finally, to confirm that A20 expression in IECs regulates wnt/
b-catenin signaling in vivo, we interbred A20FL/FL mice with mice
expressing a tamoxifen-sensitive Cre recombinase under the villin
gene promoter elements (villin-ER/Cre) [47]. Intra-peritoneal
injection of tamoxifen into compound A20FL/FL villin-ER/Cre
and control A20+/+ villin-ER/Cre mice led to reduction of A20
mRNA expression and increased expression of the b-catenin
dependent cyclinD1 and c-myc mRNAs in purified intestinal
epithelial cells (Fig. 4). These genes are also increased in human
colonic adenomas (Fig. S1). Thus, A20 restricts b-catenin
dependent signaling in vitro and in vivo.
In summary, we have discovered that the ubiquitin-modifying
enzyme A20 is a tumor suppressor for colon carcinogenesis. This
tumor suppressor function appears to be due to a novel function
for A20 in restricting wnt induced b-catenin signaling. The
relevance of our findings to human disease is high, as reduced A20
expression is a common epigenetic finding in human adenomas,
and as the increased tumorigenesis of A20FL/FL APCmin/+ mice
appears to be selective for colonic tissue, where most human
intestinal cancers occur. Our findings extend A20’s tumor
suppressor function from B cell lymphomas to colon cancers.
Finally, these studies demonstrate that A20, a potent regulator of
multiple human autoimmune and inflammatory diseases, is also
broadly important for preventing malignant transformation.
Supporting Information
Figure S1 Decreased A20 expression correlates with
increased Cyclin D1 and MYC expression in colonic
adenomas obtained from patients compared to sur-
rounding normal mucosa. Data derived from the Genome
Expression Omnibus (GDS2947).
(TIF)
Figure S2 Endogenous A20 Interaction with Axin. A) A20
deficient RKO cells generated by TALEN technology (left) or
wild-type RKO cells (right) were stimulated with TNF-a for two
hours prior to lysis. Immunoprecipitation of endogenous A20
using either the B5 or 4H16 antibody from Santa Cruz
Biotechnology efficiently co-immunoprecipitated endogenous
Axin. Inputs are shown below. GAPDH is shown as a loading
control. B) MYC tagged Axin or MYC-tagged vector control was
co-expressed with FLAG-tagged A20 or FLAG-tagged vector
control. Immunoprecipitation was performed with anti-Axin
antibody and western blot was performed with the anti-FLAG
antibody. Input levels of FLAG, MYC, and GAPDH proteins
shown below as controls.
(TIF)
Figure S3 A20 does not suppress b-catenin mRNA
expression. RKO cells transfected with either A20 specific or
control siRNAs were stimulated with wnt3a for the indicated
times. Total RNA was isolated and subjected to qPCR analysis for
b-catenin expression. Positive control is a plasmid expressing b-
catenin.
(TIF)
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